Lidoflazine structure
|
Common Name | Lidoflazine | ||
---|---|---|---|---|
CAS Number | 3416-26-0 | Molecular Weight | 491.61500 | |
Density | 1.161g/cm3 | Boiling Point | 632.6ºC at 760mmHg | |
Molecular Formula | C30H35F2N3O | Melting Point | 158-162ºC | |
MSDS | Chinese USA | Flash Point | 336.4ºC |
Use of LidoflazineLidoflazine is a high affinity blocker of the HERG (human ether-a-go-go-related gene) K+ channel. Lidoflazine is an antianginal calcium channel blocker that carries a significant risk of QT interval prolongation and ventricular arrhythmia[1]. |
Name | Lidoflazine |
---|---|
Synonym | More Synonyms |
Description | Lidoflazine is a high affinity blocker of the HERG (human ether-a-go-go-related gene) K+ channel. Lidoflazine is an antianginal calcium channel blocker that carries a significant risk of QT interval prolongation and ventricular arrhythmia[1]. |
---|---|
Target |
Ca2+ |
In Vitro | Lidoflazine inhibits potently HERG current (IHERG) recorded from HEK 293 cells stably expressing wild-type HERG (IC50 of ~16 nM). |
References |
Density | 1.161g/cm3 |
---|---|
Boiling Point | 632.6ºC at 760mmHg |
Melting Point | 158-162ºC |
Molecular Formula | C30H35F2N3O |
Molecular Weight | 491.61500 |
Flash Point | 336.4ºC |
Exact Mass | 491.27500 |
PSA | 35.58000 |
LogP | 5.69880 |
Appearance of Characters | white |
Index of Refraction | 1.581 |
Storage condition | 2-8°C |
Water Solubility | DMSO: ≥10mg/mL |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
---|---|
Hazard Codes | Xn: Harmful; |
Risk Phrases | R22 |
Safety Phrases | 36 |
RIDADR | NONH for all modes of transport |
RTECS | TK7910000 |
Protective effects of the lazaroid U74500A and lidoflazine on liver preservation with UW solution.
Transpl. Int. 6(5) , 281-4, (1993) The effect of adding a 21-aminosteroid, U74500A, and a Ca2+ antagonist, lidoflazine, alone and together to UW solution was assessed in a rat liver preservation model. Following preservation, the liver... |
|
Simpson's paradox and clinical trials: what you find is not necessarily what you prove.
Ann. Emerg. Med. 21(12) , 1480-2, (1992) Expensive clinical trials have become the gold standard for evaluating the efficacy of promising new therapeutic agents. Full exploration of the collected data is routine to maximize the yield of the ... |
|
1,4-Dihydropyridines bearing a pharmacophoric fragment of lidoflazine.
Bioorg. Med. Chem. 4(10) , 1629-35, (1996) A series of 1,4-dihydropyridines bearing a pharmacophoric fragment of lidoflazine was synthesized. The compounds were evaluated for inotropic, chronotropic, and calcium antagonist activities. All comp... |
4-[4,4-Bis(4-fluorophenyl)butyl]-N-(2,6-dimethylphenyl)-1-piperazineacetamide |
2-[4-[4,4-bis(4-fluorophenyl)butyl]piperazin-1-yl]-N-(2,6-dimethylphenyl)acetamide |